PMC:7299399 / 41447-42406 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T194","span":{"begin":388,"end":392},"obj":"Body_part"},{"id":"T195","span":{"begin":799,"end":803},"obj":"Body_part"}],"attributes":[{"id":"A194","pred":"fma_id","subj":"T194","obj":"http://purl.org/sig/ont/fma/fma74402"},{"id":"A195","pred":"fma_id","subj":"T195","obj":"http://purl.org/sig/ont/fma/fma74402"}],"text":"Fast forward a few decades, and the promises made by both worlds seem to have finally become reality, with a number of active clinical trials, some clinical success stories, and a few commercial products in the market space. Interestingly, the two worlds seem to have maintained a safe distance so as to avoid any collision or dangerous proximity. Exchange of ideas between the fields of gene therapy and nanomedicine is limited, and the potential for disciplinary growth through knowledge exchange has remained elusive to scientists in both fields.5 Many scientists have suggested that nanotechnologists could find inspiration in the mechanisms devised by viruses to elude immune surveillance, to overcome biological barriers, and to deliver their genetic payload with high specificity. Similarly, gene therapists would find high-tech solutions to their scalability and safety issues in looking at the new generations of biomimetic particles being generated."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T376","span":{"begin":13,"end":14},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T377","span":{"begin":107,"end":108},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T378","span":{"begin":119,"end":125},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T379","span":{"begin":178,"end":179},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T380","span":{"begin":279,"end":280},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T381","span":{"begin":378,"end":384},"obj":"http://purl.obolibrary.org/obo/UBERON_0007688"},{"id":"T382","span":{"begin":388,"end":392},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T383","span":{"begin":499,"end":502},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T384","span":{"begin":542,"end":548},"obj":"http://purl.obolibrary.org/obo/UBERON_0007688"},{"id":"T385","span":{"begin":657,"end":664},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T386","span":{"begin":799,"end":803},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"}],"text":"Fast forward a few decades, and the promises made by both worlds seem to have finally become reality, with a number of active clinical trials, some clinical success stories, and a few commercial products in the market space. Interestingly, the two worlds seem to have maintained a safe distance so as to avoid any collision or dangerous proximity. Exchange of ideas between the fields of gene therapy and nanomedicine is limited, and the potential for disciplinary growth through knowledge exchange has remained elusive to scientists in both fields.5 Many scientists have suggested that nanotechnologists could find inspiration in the mechanisms devised by viruses to elude immune surveillance, to overcome biological barriers, and to deliver their genetic payload with high specificity. Similarly, gene therapists would find high-tech solutions to their scalability and safety issues in looking at the new generations of biomimetic particles being generated."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T56","span":{"begin":465,"end":471},"obj":"http://purl.obolibrary.org/obo/GO_0040007"},{"id":"T57","span":{"begin":490,"end":498},"obj":"http://purl.obolibrary.org/obo/GO_0015297"}],"text":"Fast forward a few decades, and the promises made by both worlds seem to have finally become reality, with a number of active clinical trials, some clinical success stories, and a few commercial products in the market space. Interestingly, the two worlds seem to have maintained a safe distance so as to avoid any collision or dangerous proximity. Exchange of ideas between the fields of gene therapy and nanomedicine is limited, and the potential for disciplinary growth through knowledge exchange has remained elusive to scientists in both fields.5 Many scientists have suggested that nanotechnologists could find inspiration in the mechanisms devised by viruses to elude immune surveillance, to overcome biological barriers, and to deliver their genetic payload with high specificity. Similarly, gene therapists would find high-tech solutions to their scalability and safety issues in looking at the new generations of biomimetic particles being generated."}

{"project":"LitCovid-sentences","denotations":[{"id":"T160","span":{"begin":0,"end":224},"obj":"Sentence"},{"id":"T161","span":{"begin":225,"end":347},"obj":"Sentence"},{"id":"T162","span":{"begin":348,"end":787},"obj":"Sentence"},{"id":"T163","span":{"begin":788,"end":959},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Fast forward a few decades, and the promises made by both worlds seem to have finally become reality, with a number of active clinical trials, some clinical success stories, and a few commercial products in the market space. Interestingly, the two worlds seem to have maintained a safe distance so as to avoid any collision or dangerous proximity. Exchange of ideas between the fields of gene therapy and nanomedicine is limited, and the potential for disciplinary growth through knowledge exchange has remained elusive to scientists in both fields.5 Many scientists have suggested that nanotechnologists could find inspiration in the mechanisms devised by viruses to elude immune surveillance, to overcome biological barriers, and to deliver their genetic payload with high specificity. Similarly, gene therapists would find high-tech solutions to their scalability and safety issues in looking at the new generations of biomimetic particles being generated."}

{"project":"2_test","denotations":[{"id":"32519842-25022906-158545","span":{"begin":549,"end":550},"obj":"25022906"}],"text":"Fast forward a few decades, and the promises made by both worlds seem to have finally become reality, with a number of active clinical trials, some clinical success stories, and a few commercial products in the market space. Interestingly, the two worlds seem to have maintained a safe distance so as to avoid any collision or dangerous proximity. Exchange of ideas between the fields of gene therapy and nanomedicine is limited, and the potential for disciplinary growth through knowledge exchange has remained elusive to scientists in both fields.5 Many scientists have suggested that nanotechnologists could find inspiration in the mechanisms devised by viruses to elude immune surveillance, to overcome biological barriers, and to deliver their genetic payload with high specificity. Similarly, gene therapists would find high-tech solutions to their scalability and safety issues in looking at the new generations of biomimetic particles being generated."}